Log In
BCIQ
Print this Print this
 

SL-701

  Manage Alerts
Collapse Summary General Information
Company Stemline Therapeutics Inc.
DescriptionCancer immunotherapy comprised of synthetic short peptides against IL-13RA2, EPHA2 and survivin (BIRC5)
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationBrain cancer
Indication DetailsSecond-line treatment of glioblastoma multiforme (GBM); Treat glioma; Treat newly diagnosed and recurrent adult low-grade glioma; Treat newly diagnosed and recurrent pediatric glioma; Treat recurrent and refractory adult high-grade glioma; Treat recurrent glioblastoma multiforme (GBM)
Regulatory Designation U.S. - Orphan Drug (Treat glioma)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/28/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today